Hikma says it has considerably broadened access to infliximab in Morocco by introducing its Remsima biosimilar early last year. The Jordanian firm claims to have helped increase the size of the local market by about 50% to 11,000 vials per year whilst raising Remsima’s market share to more than 75%. “This example demonstrates how we grow our business and we are not limited to taking market share from the originator,” commented Hikma’s chief executive officer Siggi Olafsson.
Remsima broadens access
Hikma says it has considerably broadened access to infliximab in Morocco by introducing its Remsima biosimilar early last year. The Jordanian firm claims to have helped increase the size of the local market by about 50% to 11,000 vials per year whilst raising Remsima’s market share to more than 75%. “This example demonstrates how we grow our business and we are not limited to taking market share from the originator,” commented Hikma’s chief executive officer Siggi Olafsson.
More from Archive
More from Generics Bulletin
• By
Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.
• By
Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.
• By
A UK High Court justice came down on the side of Glenmark in AstraZeneca’s bid to enjoin the firm from launching a generic version of its Forxiga blockbuster before judgment is delivered in the firms’ patent-litigation clash.